SNY Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Zacks Investment Research - Mentions: TEVA ANIP CSTL

TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia

4 days ago - By: Zacks Investment Research - Mentions: BMY NVO TEVA

Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play

4 days ago - By: Zacks Investment Research - Mentions: ANIP CSTL KYMR

KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study

6 days ago - By: The Motley Fool - Mentions: ALNY REGN BIIB VIR ...

Is Alnylam Pharmaceuticals a Millionaire Maker?

8 days ago - By: Zacks Investment Research - Mentions: TEVA FOLD

Can Galafold Continue to Drive Amicus' Top Line in 2026?

8 days ago - By: Zacks Investment Research - Mentions: LLY JNJ

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi

a month ago - By: Zacks Investment Research - Mentions: ACN DVMT DELL

The Zacks Analyst Blog Accenture, Sanofi and Dell

2 months ago - By: Investor's Business Daily - Mentions: AAPL

Sanofi Jumps As Third-Quarter Dupixent Sales Near $5 Billion

2 months ago - By: Benzinga

Examining the Future: Sanofi's Earnings Outlook

9 days ago - By: Zacks Investment Research - Mentions: JNJ LLY

3 Large Drug Stocks to Watch as the Industry Shows Some Recovery

12 days ago - By: Investor's Business Daily - Mentions: PFE MRNA BNTX DVAX ...

Moderna, BioNTech Slammed After FDA Links Covid Shots To 10 Deaths

12 days ago - By: Zacks Investment Research - Mentions: REGN

REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?

13 days ago - By: The Motley Fool - Mentions: REGN AMGN AMD

Should You Buy This Biotech Stock That Just Gained 5% in 1 Day?

17 days ago - By: Investor's Business Daily

Sanofi Stock Drops After Confirming Raid, Tax Fraud Investigation

17 days ago - By: Zacks Investment Research - Mentions: AZN MRK

Will Soft Gardasil Demand Continue to Dampen Merck's Top Line?

17 days ago - By: Zacks Investment Research - Mentions: GILD KYMR

Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock?

19 days ago - By: Regeneron Pharmaceuticals, Inc. - Mentions: REGN

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

23 days ago - By: Zacks Investment Research - Mentions: REGN

REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD

a month ago - By: Zacks Investment Research - Mentions: ACN DVMT PEG PCG ...

Top Research Reports for Accenture, Sanofi & Dell Technologies

a month ago - By: Investor's Business Daily - Mentions: TGTX

TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results

a month ago - By: Investor's Business Daily - Mentions: MRK REGN AMGN

Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%

a month ago - By: Zacks Investment Research - Mentions: NVAX ANIP ARQT

Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised

2 months ago - By: Benzinga - Mentions: REGN

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness

2 months ago - By: Medidata Solutions, Inc.

UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey

2 months ago - By: Zacks Investment Research - Mentions: AZN MRK

Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings?